Cargando…

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease

BACKGROUND: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time‐to‐ON with levodopa are common. This open‐label study aimed to assess the effect of apomorphine on time‐to‐ON in PD patients with morning akinesia. METHODS: The safety population included 127 e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Stuart, Lew, Mark, Ondo, William, Hubble, Jean, Clinch, Thomas, Pagan, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298032/ https://www.ncbi.nlm.nih.gov/pubmed/28239615 http://dx.doi.org/10.1002/mdc3.12350

Ejemplares similares

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023)

Task Specific Tremor in Parkinson’s Disease Responds to Apomorphine
por: Ondo, William G., et al.
Publicado: (2023)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
por: Kassubek, Jan, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial
por: Isaacson, Stuart H., et al.
Publicado: (2020)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature
por: Isaacson, Stuart H., et al.
Publicado: (2022)

Apomorphine in Parkinson's Disease—The Questions Raised
por: Dhamija, Rajinder K., et al.
Publicado: (2020)

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
por: Isaacson, Stuart H., et al.
Publicado: (2022)

A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease
por: Kim, Jayoung, et al.
Publicado: (2022)

Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson’s disease patient
por: Spagnolo, Francesca, et al.
Publicado: (2021)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Functional imaging correlates of akinesia in Parkinson's disease: Still open issues
por: Spay, Charlotte, et al.
Publicado: (2018)

Ventricular Bigeminy after Subcutaneous Administration of Apomorphine in a Patient with Refractory Parkinson’s Disease: A Case Report
por: Kaminioti, Anastasia N., et al.
Publicado: (2013)

Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
por: Fernández-Pajarín, Gustavo, et al.
Publicado: (2021)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?
por: Desjardins, Clément, et al.
Publicado: (2023)

Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
por: Henriksen, Tove, et al.
Publicado: (2021)

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
por: Carbone, Federico, et al.
Publicado: (2019)

Investigation of apomorphine during sleep in Parkinson’s: Improvement in UPDRS Scores
por: Pieroni, Miguel A.
Publicado: (2019)

Apomorphine effects on the hippocampus
por: Arroyo-García, Luis Enrique, et al.
Publicado: (2018)

On the Anæsthetic Action of Apomorphine
Publicado: (1885)

Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease
por: Passamonti, Luca, et al.
Publicado: (2013)

Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
por: Borkar, Nrupa, et al.
Publicado: (2018)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
por: Patel, Atul T., et al.
Publicado: (2021)

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
por: Patel, Atul T., et al.
Publicado: (2021)

Preliminary Report on Anæsthesia and Akinesia in Intra-ocular Operations
por: Wheeler, J. R.
Publicado: (1953)

Pure akinesia with gait freezing: a clinicopathologic study
por: Elkouzi, Ahmad, et al.
Publicado: (2017)

Different Dopaminergic Dysfunctions Underlying Parkinsonian Akinesia and Tremor
por: Caligiore, Daniele, et al.
Publicado: (2019)

Some Observations on the Use of Apomorphine
por: Horsley, J. S.
Publicado: (1912)

Is Apomorphine a Safe Emetic?
por: Brown, John
Publicado: (1889)

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
por: Nishijima, Haruo, et al.
Publicado: (2018)

A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia
por: Schallert, T., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_3gqbkuoij3ovs577qauccvaagd